There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Autolus Therapeutics (AUTL) and Nucana (NCNA) with bullish sentiments.
Autolus Therapeutics (AUTL)
Needham analyst Chad Messer assigned a Buy rating to Autolus Therapeutics today and set a price target of $26.00. The company’s shares closed last Monday at $10.60.
According to TipRanks.com, Messer is a 5-star analyst with an average return of 11.7% and a 48.9% success rate. Messer covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Aeglea Biotherapeutics, and Ionis Pharmaceuticals.
Autolus Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $25.00.
See today’s analyst top recommended stocks >>
Nucana (NCNA)
According to TipRanks.com, Gershell is a 3-star analyst with an average return of 3.2% and a 41.8% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries, Milestone Pharmaceuticals, and BioMarin Pharmaceutical.
Currently, the analyst consensus on Nucana is a Moderate Buy with an average price target of $17.50, a 288.9% upside from current levels. In a report issued on November 24, H.C. Wainwright also reiterated a Buy rating on the stock with a $15.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
